Compare DexCom, Inc. (DXCM) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SiTime Corporation — how do they compare? DexCom, Inc. trades at $77.18 (market cap $28.06B), while SiTime Corporation trades at $563.78 (market cap $18.34B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| DXCM | SITM | |
|---|---|---|
Market Cap | $28.06B | $18.34B |
Sector | Health | Technology |
52-Week High | $89.53 | $901.60 |
52-Week Low | $54.84 | $190.16 |
Enterprise Value | $27.03B | $17.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
SITM is trading at $561.29, down 10.03% today, showing bearish technical signals despite strong analyst support. The company demonstrates impressive revenue growth with Q1 2026 earnings beating expectations at $1.44 per share versus $1.16 expected. Recent completion of Renesas timing business acquisition and strong AI-driven demand provide growth catalysts, though negative net margins and high valuation ratios present fundamental concerns.
The outlook remains mixed with 100% analyst buy ratings and $825 consensus price target suggesting 47% upside potential, but technical weakness and negative profitability metrics warrant caution. Key risks include execution of growth initiatives and competitive pressures in the timing semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
